
Sarepta Therapeutics, Inc.: updates and filings
Price
$14.53
November 18, 2026Market cap $1.5B
What Ploutos Investor adds for Sarepta Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Its own holdings as an investment manager (13F)Form13F-HR
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 5, 2026Results of operationsForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Sep 23, 2026Material agreement enteredForm8-K
- Aug 14, 2026Its own holdings as an investment manager (13F)Form13F-HR
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 5, 2026Results of operationsForm8-K
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 31, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 28, 2026Shares registered for employeesFormS-8
- Jul 27, 2026Officer or director change, Regulation FD disclosureForm8-K
- Jun 4, 2026Shares registered for employeesFormS-8
- Jun 4, 2026Officer or director change, shareholder voteForm8-K
- May 13, 2026Its own holdings as an investment manager (13F)Form13F-HR
- May 6, 2026Results of operationsForm8-K
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 24, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 24, 2026Additional annual meeting materialFormDEFA14A
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Sep 23, 2026 | 8-K | Material agreement entered | Document |
| Aug 14, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 31, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 28, 2026 | S-8 | Shares registered for employees | Document |
| Jul 27, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Jun 4, 2026 | S-8 | Shares registered for employees | Document |
| Jun 4, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 13, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 24, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 24, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 28, 1997. Of its note and share prospectuses (424B, FWP), the newest 40 of 48.
The full analysis
What do Sarepta Therapeutics's filings show?
The filings are where every one of Sarepta Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.